Financial Data and Key Metrics Changes - GAAP net income allocable to common shares for Q3 2024 was $2.8 million or $0.36 per share diluted, compared to previous periods [13] - GAAP book value per share increased to $27.92 on September 30 from $27.20 on June 30 [17] - Earnings available for distribution (EAD) for Q3 was $0.24 per share, down from $0.51 per share in Q2 [16] Business Line Data and Key Metrics Changes - Loan payoffs during the period were $118.1 million, with foreclosures totaling $23.7 million, resulting in a net decrease to the loan portfolio of $134.4 million [8] - The weighted average spread of floating rate loans in the $1.6 billion commercial real estate loan portfolio is now 3.73% over one-month term SOFR rates [8] - The total allowance for credit losses at September 30 was $34.7 million, representing 2.19% of the loan portfolio [15] Market Data and Key Metrics Changes - The company ended the quarter with $1.6 billion of commercial real estate loans across 56 individual investments, with 23% of the par value rated four or five [9] - The weighted average risk rating remained stable at 2.7% for both June 30 and September 30 [9] Company Strategy and Development Direction - The company is focused on monetizing assets and reinvesting potential gains into the loan portfolio, with a strategy to improve credit quality and recycle capital into performing assets [10][12] - Management aims to drive earnings and book value for shareholders while preparing for a market-based dividend over the next 12 months [21] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the quality of the investment portfolio and anticipated gains from real estate investments, despite some macroeconomic challenges [14][20] - The company expects to complete monetization efforts over the next two quarters, which will positively impact book value per share [20] Other Important Information - The company used $1.7 million to repurchase 114,000 common shares at a significant discount to book value, with approximately $2.3 million remaining on the repurchase program [18] - Available liquidity at September 30 was $79 million, consisting of $70 million in unrestricted cash and $9.7 million in projected financing [18] Q&A Session Summary Question: Are you looking to fully clear equity assets and REO before turning to originations? - Management indicated they will monetize and redeploy gradually, not waiting for full completion [23] Question: What are the targets for getting dividends back up? - Management has not set specific targets but aims to drive EAD and pay dividends based on that [24] Question: How much was used for share repurchases this quarter? - $1.7 million was used for repurchases, with $2.3 million remaining on the program [26] Question: Can you discuss near-term liquidations of assets? - Management mentioned three other assets are in process for execution over the next couple of quarters [28] Question: How is the loan pipeline ramping up? - Management stated they are engaged in the marketplace and expect to allocate some origination to the REIT once liquidity is appropriate [30] Question: What are the expectations for unrealized gains on REO conversion? - Management categorized expected gains as incremental but did not provide specific projections [38]

| --- | --- | --- | --- | --- | --- | |-------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | THIRD QUARTER 2024 EARNINGS PRESENTATION | | | | | | | October 30, 2024 | | | | | | | | | | | | | DISCLAIMER ACRESREIT.COM 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements are not historical facts but rather are based on ACRES Commercial Realty ...

分组1 - ACRES Commercial reported quarterly earnings of $0.24 per share, missing the Zacks Consensus Estimate of $0.39 per share, and down from $0.73 per share a year ago, representing an earnings surprise of -38.46% [1] - The company posted revenues of $10.46 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 1.33%, and down from $14.65 million year-over-year [2] - Over the last four quarters, ACRES Commercial has surpassed consensus EPS estimates only once and has not beaten consensus revenue estimates during the same period [2] 分组2 - ACRES Commercial shares have increased approximately 54.6% since the beginning of the year, outperforming the S&P 500's gain of 22.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.38 on revenues of $10.9 million, and for the current fiscal year, it is $1.43 on revenues of $43.6 million [7] - The REIT and Equity Trust industry, to which ACRES Commercial belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share ACR New York Stock Exchange 8.625% Fixed-to-Floating Series C Cumulative Redeemable Preferred Stock ACRPrC New York Stock Exchange 7.875% Series D Cumulative Redeemable Preferred Stock ACRPrD New York Stock Exchange FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of ...

Core Insights - Protalix BioTherapeutics is set to present data from a phase I clinical trial of PRX-115, a recombinant PEGylated uricase for uncontrolled gout, at the ACR Convergence 2024 [1] - The presentation will highlight the prolonged plasma urate-lowering effects after a single intravenous administration of PRX-115 [1] Company Overview - Protalix BioTherapeutics specializes in developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system [2] - The company was the first to receive FDA approval for a protein produced through a plant cell-based expression system [2] - Protalix has licensed worldwide rights for taliglucerase alfa, its first product, to Pfizer, while retaining full rights in Brazil [2] Product Pipeline - Protalix's development pipeline includes PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases, among other proprietary recombinant therapeutic proteins [3]

SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that preclinical data will be presented from NX-5948, Nurix’s proprietary BTK degrader currently in Phase 1b development for B-cell malignancies and in IND enabling studies for autoimmune disease, and GS-6791/NX-0479, an IRAK4 degrader discovered in co ...

Core Insights - Kronos Bio, Inc. is developing a p300 KAT inhibitor aimed at treating autoimmune diseases, with preclinical data to be presented at the ACR Convergence 2024 meeting [1][2][3] - The company is on track to announce a development candidate for autoimmune diseases by the end of 2024 [2][3] Company Overview - Kronos Bio is a clinical-stage company focused on small molecule therapeutics that target deregulated transcription, which is associated with cancer and other diseases [4] - The company utilizes a proprietary discovery engine to decode transcription factor regulatory networks, identifying druggable cofactors for therapeutic development [4] - Kronos Bio has a preclinical pipeline that includes two drug candidates: KB-0742 targeting CDK9 for MYC deregulation in solid tumors and KB-9558 targeting p300 for IRF4 dependence in multiple myeloma [4]

ACRES Commercial Realty (NYSE: ACR ) last paid a quarterly cash dividend in January 2020. This was a few months before the pandemic would spark global stay-at-home orders and roughly two years before mortgage REITs would faceThe equity market is a powerful mechanism as daily fluctuations in price get aggregated to incredible wealth creation or destruction over the long term. Pacifica Yield aims to pursue long-term wealth creation with a focus on undervalued yet high-growth companies, high-dividend tickers, ...

Acrivon Therapeutics, Inc. (NASDAQ: ACRV ), a relatively under-the-radar player in the biotech universe, has been quietly making waves in the precision oncology space. Leveraging its proprietary proteomics platform, ACRV is developing targeted therapies that could revolutionizeAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my ...

Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically significant segregation of responders in BM+ vs BM- subgroups based on OncoSignature patient selection (p-value = 0.009) ACR-368 endometrial cohort data maturing with all responders still on therapy; mDoR not yet reached (~6 months at time of data-cut) Endometrial cancer now anticipated to be the first tumor type wit ...